DUX4 and facioscapulohumeral muscular dystrophy: In particular, xenograft models of FSHD are the only setting in which therapeutic approaches targeting the FSHD locus and DUX4 epigenetic or transcriptional regulation [157,159,160,161,162,163,164,165] can be tested in vivo.